The 24th International AIDS Conference (AIDS 2022)

Post-exposure doxycycline prevents STIs in MSM, TGW with HIV or on PrEP

Roshini Claire Anthony, 20221005180001

Doxycycline, taken with 72 hours of unprotected sex, could prevent sexually transmitted infections (STIs) in men who have sex with men (MSM) or transgender women (TGW) who are either living with HIV (PLHIV) or are receiving pre-exposure prophylaxis (PrEP), according to a study presented at AIDS 2022.

Dual therapy as good as triple therapy for treatment-naïve HIV

Elvira Manzano, 20220831000000

Dual therapy with the fixed-dose combination of darunavir/ritonavir plus lamivudine effectively controlled HIV as the same combination with tenofovir in treatment-naïve patients with HIV, according to the phase IV ANDES trial presented at AIDS 2022.

B/F/TAF combo: A better choice than DTG+F/TDF in patients with HIV/HBV co-infection?

Trial of two tenofovir-containing regimens for HIV/HBV co-infection: Insights from ALLIANCE

Roshini Claire Anthony, 20220824180001

The triplet combination of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is as good as dolutegravir + emtricitabine/tenofovir disoproxil fumarate (DTG+F/TDF) in terms of efficacy for HIV control but results in better hepatitis B virus (HBV) outcomes in patients with HIV/HBV co-infection, according to results of the phase III ALLIANCE trial presented at IAS 2022.

Does TB influence viral suppression in HIV patients on DTG-based therapy?

Audrey Abella, 20220816100000

Incident tuberculosis (TB) appears to be a risk factor for virologic non-suppression (ie, viral load of >1,000 copies/mL) in HIV patients who have transitioned to dolutegravir (DTG)-based therapy with recycled NRTIs*, according to a retrospective subanalysis of the VISEND study.

Another breakthrough for HIV: Fourth patient goes into long-term remission

Audrey Abella, 20220812100000

Hope springs yet again in the field of HIV treatment, as another HIV patient (reportedly the fourth in the world) goes into remission 3 decades following diagnosis. The patient stopped antiretroviral therapy (ART) after receiving allogeneic hematopoietic stem cell transplantation (HCT) of CCR5-Δ32/Δ32 donor cells for acute myelogenous leukaemia (AML).

Negative attitude towards MSM living with HIV tied to low knowledge, worry about HIV

Stephen Padilla, 20220808120000

Ignorance and fear of HIV both contribute significantly to the negative attitudes towards men who have sex with men (MSM) living with the virus, suggests a study presented at the 24th International AIDS Conference (AIDS 2022) in Montreal, Canada.

Long-acting injectable HIV drug works for all ages

Jairia Dela Cruz, 20220807080000

The long-acting combination of cabotegravir plus rilpivirine, administered as monthly or once-every-2-months jabs, appears to be effective in both older and younger patients living with HIV, with most maintaining virologic suppression through week 96, according to pooled data from the phase III ATLAS, FLAIR, and ATLAS-2M studies.

HIV intervention uptake remains low among transgender men; campaign helps

Stephen Padilla, 20220805120000

Transgender individuals, particularly transgender men (TGM), show poor acceptance of HIV prevention interventions (HPI) in the Philippines, according to a study presented at the AIDS 2022 conference in Montreal, Canada. Although some transgender individuals who prefer having sex with men make use of HPI, it remains relatively lower among TGM who have sex with men (SM).

One in five women living with HIV engages in drinking, smoking

Tristan Manalac, 20220805090000

Co-occurring and long-term heavy drinking, smoking, and depressive symptoms are common among women living with HIV, according to a study presented at the 24th International AIDS Conference (AIDS 2022). In turn, such sustained syndemics appear to worsen mortality in this population.

Expectant mums’ use of dolutegravir safe for babies

Jairia Dela Cruz, 20220804140000

Treatment with dolutegravir during pregnancy does not appear to pose an excess risk of adverse birth outcomes, according to two studies presented at the 24th International AIDS Conference in Montreal, Canada.